WinQ : a Window of Opportunity Study With MitoQ in Breast Cancer

Recruiting now · Not applicable

Conditions studied: Breast Cancer

In brief

The purpose of the study is to validate biomarkers in blood and tumor biopsy in patients with Triple Negative Breast Cancer, after a course of MitoQ treatment

Key facts

Study ID

NCT07142096

Run by

Université Catholique de Louvain

People needed

20

Starts

2025-07-20

Expected to finish

2026-07-20

Last updated by the study team

2025-08-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet the following criteria for study entry:
• Signed Informed Consent Form (ICF)
• Ability to comply with protocol, in the investigator's judgment
• Women aged > 18 years (no limit of age)
• ECOG performance status of 0 or 1
• Histologically documented TNBC (negative ER, - PR and HER2, status); HER2 negativity will be defined using ISH or IHC assays per ASCO/CAP criteria [1] and ER/PR negativity will be defined with < 10% tumor cells with ER/PgR staining using IHC. Patients with multifocal, multicentric or bilateral tumors are eligible, provided all discrete lesions are sampled and confirmed as triple- negative.
• Histologically confirmed invasive breast carcinoma
• Patient agreement to undergo appropriate systemic and surgical management after completion of window treatment
• Adequate hematologic and end-organ function, as defined by the following laboratory results obtained within 14 days prior to the first study treatment:
• ANC > 1500 cells/µL (without granulocyte colony-stimulating factor support within
• 2 weeks prior to Cycle 1, Day 1)
• Platelet count > 100,000/µL (without transfusion within 2 weeks prior to Cycle 1, Day 1)
• Hemoglobin > 9.0 g/dL
• Patients may be transfused to meet this criterion.
• AST, ALT, and alkaline phosphatase
• < 2.5 x the upper limit of normal (ULN)
• Serum bilirubin < 1.0 x ULN
• Patients with known Gilbert disease: serum bilirubin level < 3 x ULN
• For patients not receiving therapeutic anticoagulation: INR or aPTT < 1.5 x ULN within 14 days prior to initiation of study treatment
• For patients receiving therapeutic anticoagulation: INR or aPTT within therapeutic limits for at least 1 week immediately prior to initiation of study treatment
• For patients receiving therapeutic anticoagulation: stable anticoagulant regimen and stable INR during the 14 days immediately preceding initiation of study treatment
• Creatinine clearance > 30 mL/min (calculated using the Cockcroft-Gault formula)
• Serum albumin > 2.5 g/dL
• Beta-HCG negative if applicable (cfr infra)
• Representative formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least 20 unstained slides, with an associated pathology report documenting ER, PR, and HER2 negativity. Tumor tissue should be of good quality based on total and viable tumor content.

You may not qualify if…

• Men
• Prior systemic therapy for treatment and prevention of the current breast cancer
• Known allergy or hypersensitivity to MitoQ
• Known active viral hepatitis
• Known human immunodeficiency virus infection with detectable viral load
• Active tuberculosis
• Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
• Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a food supplement or that may affect the interpretation of the results or render the patient at high risk from treatment complications
• Pregnant or lactating, or intending to become pregnant during the study Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.
• Patients included in the study should not be under fertility preservation procedures because of the unknown effect of the treatment during human pregnancy.

Where it is running

• Cliniques universitaires Saint-Luc — Brussels, Belgium (enrolling)
• Cliniques universitaires Saint-Luc — Brussels, Belgium

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.